Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline

Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment. With 132 hedge funds holding the stock as of Q1 2026, Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now.

​Recently, on June 9, Goldman Sachs analyst Asad Haider reiterated a Buy rating on the stock with a price target of $1,283. The analyst noted the company’s expanding growth pipeline of obesity treatment as a key driver of the bullish sentiment. Haider highlighted Lilly’s Retatrutide, which is showing strong efficacy at a lower 4 mg dose and delivers weight loss comparable to Zepbound’s highest dose. The analyst noted that the simpler titration schedule and better tolerability of the drug suggest a much broader patient base than previously anticipated.

​Moreover, the firm also points to Eloralintide, which is a differentiated amylin agonist offering double-digit weight loss with placebo-like tolerability and no titration required. The analyst believes that this position makes Eloralintide a more accessible alternative to current GLP-1 therapies and a cornerstone of one of Lilly’s most expansive development programs.

​Goldman Sachs sees potential for upward revisions as potential launches are expected in 2027 and 2028.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Most Undervalued Foreign Stocks to Buy Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1